FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2988614685> ?p ?o ?g. }

• W2988614685 endingPage "1827" @default.
• W2988614685 startingPage "1820" @default.
• W2988614685 abstract "Background: Rates of adverse events with sorafenib were higher in the DECISION trial in radioactive iodine-refractory, advanced differentiated thyroid cancer (DTC) than in trials of sorafenib for other tumor types. One possible explanation is that sarcopenia, a known predictive factor of toxicity in patients with cancer, is more common in patients with DTC due to hormone suppressive therapy. Methods: This retrospective exploratory analysis was performed to assess whether the risk of early toxicity leading to dose modification (DMT) with sorafenib was higher in patients with sarcopenia compared with those without sarcopenia. The data set comprised patients from the phase III DECISION trial with a computed tomography scan available to determine muscle mass. The skeletal muscle (SM) cross-sectional area was used to determine the SM index and define sarcopenia. The end points were changes in body composition, DMT, early DMT (within 1 month), severe toxic events (STEs), and early STEs. Results: Overall, 365 patients were eligible for this analysis; baseline characteristics were well balanced between patients receiving sorafenib (n = 180) versus placebo (n = 185). Using a sarcopenia definition of an SM index less than the median sex-specific SM index, approximately half of the patients receiving sorafenib were at risk of sarcopenia (89/180; 49.4%), with wide geographical variation. At 6 months, the mean weight, body mass index, and lean body mass of patients receiving sorafenib were lower than at baseline and significantly lower than for patients receiving placebo (all p < 0.0001). Most DMTs and STEs occurred in the first month of treatment. There was a nonsignificant trend for more early DMTs in patients with sarcopenia compared with those without sarcopenia (55.3% vs. 44.7%, respectively; p = 0.2273). Conclusions: These results show a significant effect of sorafenib on muscle mass. However, there was no association between sarcopenia and DMT or early DMT, in contrast to observations in hepatocellular and renal cell carcinoma." @default.
• W2988614685 created "2019-11-22" @default.
• W2988614685 creator A5009392187 @default.
• W2988614685 creator A5009896278 @default.
• W2988614685 creator A5027783041 @default.
• W2988614685 creator A5039428493 @default.
• W2988614685 creator A5041250553 @default.
• W2988614685 creator A5043315417 @default.
• W2988614685 creator A5062458237 @default.
• W2988614685 creator A5065121477 @default.
• W2988614685 creator A5073411202 @default.
• W2988614685 creator A5088471251 @default.
• W2988614685 date "2019-12-01" @default.
• W2988614685 modified "2023-10-13" @default.
• W2988614685 title "Body Composition in Patients with Radioactive Iodine-Refractory, Advanced Differentiated Thyroid Cancer Treated with Sorafenib or Placebo: A Retrospective Analysis of the Phase III DECISION Trial" @default.
• W2988614685 cites W1967412279 @default.
• W2988614685 cites W1969676110 @default.
• W2988614685 cites W1971837077 @default.
• W2988614685 cites W1978713285 @default.
• W2988614685 cites W1999966467 @default.
• W2988614685 cites W2006782694 @default.
• W2988614685 cites W2013439462 @default.
• W2988614685 cites W2054865212 @default.
• W2988614685 cites W2073095675 @default.
• W2988614685 cites W2100969445 @default.
• W2988614685 cites W2101398993 @default.
• W2988614685 cites W2118558111 @default.
• W2988614685 cites W2140167330 @default.
• W2988614685 cites W2140765540 @default.
• W2988614685 cites W2145280166 @default.
• W2988614685 cites W2154493372 @default.
• W2988614685 cites W2158151049 @default.
• W2988614685 cites W2166926027 @default.
• W2988614685 cites W2168076926 @default.
• W2988614685 cites W2233885649 @default.
• W2988614685 cites W2268912046 @default.
• W2988614685 cites W2302595034 @default.
• W2988614685 cites W2345515755 @default.
• W2988614685 cites W2472346384 @default.
• W2988614685 cites W2492645252 @default.
• W2988614685 cites W2505149831 @default.
• W2988614685 cites W2617892439 @default.
• W2988614685 cites W2619069011 @default.
• W2988614685 cites W2701848515 @default.
• W2988614685 cites W2807042906 @default.
• W2988614685 cites W2951653362 @default.
• W2988614685 doi "https://doi.org/10.1089/thy.2018.0784" @default.
• W2988614685 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6918875" @default.
• W2988614685 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31860408" @default.
• W2988614685 hasPublicationYear "2019" @default.
• W2988614685 type Work @default.
• W2988614685 sameAs 2988614685 @default.
• W2988614685 citedByCount "12" @default.
• W2988614685 countsByYear W29886146852020 @default.
• W2988614685 countsByYear W29886146852021 @default.
• W2988614685 countsByYear W29886146852022 @default.
• W2988614685 countsByYear W29886146852023 @default.
• W2988614685 crossrefType "journal-article" @default.
• W2988614685 hasAuthorship W2988614685A5009392187 @default.
• W2988614685 hasAuthorship W2988614685A5009896278 @default.
• W2988614685 hasAuthorship W2988614685A5027783041 @default.
• W2988614685 hasAuthorship W2988614685A5039428493 @default.
• W2988614685 hasAuthorship W2988614685A5041250553 @default.
• W2988614685 hasAuthorship W2988614685A5043315417 @default.
• W2988614685 hasAuthorship W2988614685A5062458237 @default.
• W2988614685 hasAuthorship W2988614685A5065121477 @default.
• W2988614685 hasAuthorship W2988614685A5073411202 @default.
• W2988614685 hasAuthorship W2988614685A5088471251 @default.
• W2988614685 hasBestOaLocation W29886146852 @default.
• W2988614685 hasConcept C121332964 @default.
• W2988614685 hasConcept C121608353 @default.
• W2988614685 hasConcept C126322002 @default.
• W2988614685 hasConcept C141071460 @default.
• W2988614685 hasConcept C142424586 @default.
• W2988614685 hasConcept C142724271 @default.
• W2988614685 hasConcept C143998085 @default.
• W2988614685 hasConcept C167135981 @default.
• W2988614685 hasConcept C204787440 @default.
• W2988614685 hasConcept C27081682 @default.
• W2988614685 hasConcept C2776214593 @default.
• W2988614685 hasConcept C2778019345 @default.
• W2988614685 hasConcept C2778695046 @default.
• W2988614685 hasConcept C2779761222 @default.
• W2988614685 hasConcept C2780221984 @default.
• W2988614685 hasConcept C535046627 @default.
• W2988614685 hasConcept C71924100 @default.
• W2988614685 hasConcept C87355193 @default.
• W2988614685 hasConceptScore W2988614685C121332964 @default.
• W2988614685 hasConceptScore W2988614685C121608353 @default.
• W2988614685 hasConceptScore W2988614685C126322002 @default.
• W2988614685 hasConceptScore W2988614685C141071460 @default.
• W2988614685 hasConceptScore W2988614685C142424586 @default.
• W2988614685 hasConceptScore W2988614685C142724271 @default.
• W2988614685 hasConceptScore W2988614685C143998085 @default.
• W2988614685 hasConceptScore W2988614685C167135981 @default.
• W2988614685 hasConceptScore W2988614685C204787440 @default.
• W2988614685 hasConceptScore W2988614685C27081682 @default.
• W2988614685 hasConceptScore W2988614685C2776214593 @default.

• next